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ABSTRACT 
Malaria still affects around 200 million people and is responsible for more than 400,000 deaths per 
year, mostly children in subequatorial areas. This disease is caused by parasites of the Plasmodium genus. 
Only a few WHO-recommended treatments are available to prevent or cure plasmodial infections, but 
genetic mutations in the causal parasites have led to onset of resistance against all commercial antimalarial 
drugs. New drugs and targets are being investigated to cope with this emerging problem, including 
enzymes belonging to the main metabolic pathways, while nucleoside and nucleotide analogues are also 
a promising class of potential drugs. This review highlights the main metabolic pathways targeted for the 
development of potential antiplasmodial therapies based on nucleos(t)ide analogues, as well as the 
different series of purine-containing nucleoside and nucleotide derivatives designed to inhibit Plasmodium 
falciparum purine metabolism. 
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INTRODUCTION 
 WHO, in 2018, reported more than 435,000 deaths associated with malaria, and at least 219 million 
people—mostly children—are still affected by this disease in 91 countries located in Africa and Asia.1 The 
disease, which represents an endemic in tropical areas, is caused by protozoal parasites of the Plasmodium 
genus in the Apicomplexa phylum. Among the six human Plasmodium species (P. falciparum, P. vivax, P. 
malariae, P. ovale curtisi, P. ovale wallikeri 2,3 and P. knowlesi originally known to cause simian malaria), 
P. falciparum is the most widespread and lethal. The parasite is transmitted to humans by female mosquitos 
of the Anopheles genus (Figure 1). Plasmodium begins its development cycle in humans by multiplication 
in hepatocytes. After 10-12 days, the parasites are released in the blood and invade the erythrocytes 
(asexual multiplication). This intraerythrocytic phase constitutes the symptomatic phase of the disease, 
with massive destruction of erythrocytes and sometimes adherence to blood vessels of large organs like 
the brain, thus restricting the blood flow with serious consequences. A small proportion of the blood stages 
develop into sexual forms (so-called gametocytes) that are ingested by a feeding mosquito, therefore 
completing the cycle. Parasites of the P. vivax and P. ovale species can persist for years as dormant stages 
in the liver (so-called hypnozoites) and can cause relapses.  
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Figure 1 : Plasmodium falciparum life-cycle 
Since the historical use of quinine 400 years ago, particularly as of the late 19th century, several 
treatments of synthetic or natural origins have been developed (Figure 2) and have been successfully used 
to cure malarial diseases in infected human hosts. The various classes of antimalarial drugs belong to a 
few families according to their chemical structures, such as: aryl amino alcohols (quinine, mefloquine, 
halofantrine, etc.); 4-aminoquinolines (chloroquine, amodiaquine, piperaquine, etc.); 8-aminoquinolines 
(primaquine, tafenoquine), antifolates (proguanyl, pyrimethamine, sulfadoxine, dapsone, etc.); 
naphthoquinones (atovaquone); peroxides and sesquiterpene derivatives (artemisinin, artesunate, 
artemether, etc.); antimicrobials (tetracycline, azithromycin, fluoroquinolones, etc.). In addition to 
chemotherapy, an efficient vaccine would be a desirable tool to control and eventually eradicate malaria, 
but such a vaccine has yet to be validated despite clinical assays.4,5  
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Figure 2: Timeline of main antimalarials and occurring resistance 
Blue pills: first used as antimalarial; red circles: first reported resistance; black circles: no longer marketed 
AS/AQ, artesunate/amodiaquine; DHA-PPQ, dihydroartemisinin-piperaquine; A/P, atovaquone/proguanil; A/L, 
artemether/lumefantrine; ASSP, artesunate sufadoxine pyrimethamine; S/P, sulfadoxine/pyrimethamine; AS/MQ, 
arestunate/mefloquine; ACTs, artemisinin combination therapies; and C/D, chlorproguanil/dapsone. 
 
Mutations in the parasite genome have appeared over the last century, inducing fast spreading 
resistance against all commercial drugs (Figure 2). To address these issues, and in the absence of an 
available efficient vaccine, new drugs with original modes of action are crucial as resistance to front-line 
antimalarial drugs (essentially artemisinin-based combination therapies, ACTs) is spreading in Southeast 
Asia. A number of collaborative drug discovery programs have thus been initiated worldwide and a few 
drug candidates are currently under clinical development or have recently been approved for clinical use. 
Among them, most of the new drugs correspond to compounds that are structurally related to previously 
used drugs or artemisinin-based combinations, and some molecules with a novel mechanism of action 
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have been proposed. To our knowledge, none of them belong to the nucleos(t)ide analogue family, 
targeting proteins involved in purine or pyrimidine metabolism, except DSM265 (currently in phase IIa 
clinical trials).6 The latter is a selective inhibitor of Plasmodium dihydroorotate dehydrogenase 
(PfDHODH), which plays a central role within the de novo pyrimidine pathway. However, target 
mutations were found in patient's parasites (already observed in earlier in vitro studies) and concerned a 
few patients with recurrence at day 28 after receiving a single oral dose of DSM265. Once again, this data 
highlights the need to use combination therapies. 
 
Herein, we will focus on nucleobase, nucleoside and nucleotide analogues, which so far have been 
reported to target and inhibit proteins involved in the purine salvage pathway of Plasmodium falciparum. 
This family of derivatives is of special interest as they can mimic the endogenous substrates of these 
proteins, so the design of analogues and their study may result in a new class of antimalarial drugs. In 
addition, as Plasmodium falciparum relies solely on the de novo pathway for pyrimidine nucleotide 
biosynthesis and on the salvage pathway for purine nucleotides, both metabolic processes appear to be 
attractive chemotherapeutic targets. The development of these analogues as inhibitors of plasmodial 
purine metabolism is relatively recent and somehow associated with the discovery of the antiviral and 
antitumoral potential of such compounds. The main nucleic acid biosynthesis pathways of Plasmodium 
will be described as well as the wide collection of analogues targeting the corresponding proteins.  
 
I/ NUCLEIC ACID METABOLISM IN PLASMODIUM FALCIPARUM  
Mammalian cells are able to synthesize nucleic acids from small molecules through the de novo 
pathway but requiring 6 ATP equivalents for the synthesis of IMP from ribose-5-phosphate and a dozen 
steps. In contrast, the salvage pathway is based on the recycling of related metabolites, which is less 
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energy-demanding (a single step from hypoxanthine to IMP and 1 ATP equivalent is required for 
phosphoribosylpyrophosphate formation). The human host has both pathways to produce purine and 
pyrimidine nucleotides, whereas protozoan parasites such as Plasmodium only possess the salvage 
pathway for purine containing derivatives and de novo synthesis of pyrimidine derivatives. The latter are 
therefore essential for parasite growth, which requires a huge amount of purine and pyrimidine nucleoside 
triphosphates for its nucleic acid biosynthesis. A few reviews have provided detailed accounts of purine 
and pyrimidine pathways as chemotherapeutic targets.7–9 
 
1) Pyrimidine Metabolism 
Protozoan parasites rely solely on the de novo pathway to produce their pyrimidine derivatives, 
and they are not very capable of salvaging pyrimidines from erythrocytes. Briefly, Pf pyrimidine 
biosynthesis involves six enzymatic steps (Figure 3) as in the human host producing a central metabolite, 
i.e. uridine-5’-monophosphate (UMP), which is then used as precursor for all pyrimidine nucleotides 
(dUMP, dCTP, dTTP, UTP and CTP) required for DNA/RNA biosynthesis. The related enzymes can be 
divided in two groups of monofunctional and multifunctional proteins, i.e. the first and last three, 
respectively. Little attention has been focused on carbamoyl phosphate synthetase (CPS II) and aspartate 
transcarbamoylase (ATC), whereas Pf dihydroorotase (DHOase) has received much attention. The latter 
has been characterized and found to share many properties with mammalian proteins.10 The three 
following enzymes, i.e. orotate phosphoribosyltransferase (OPRT), dihydroorotate hydrogenase (DHODH) 
and dihydroorotase (DHOase), are considered as key enzymes to target the human parasite, and DHODH 
is one of the most widely studied.11,12 Their 3D crystal structures have been solved, their characteristics 
have been studied in detail and compared to their human counterpart. 
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This review is not intended to provide a detailed account of these proteins and their inhibitors, but 
these data may be gleaned from the literature7,13 
 
Figure 3 : Pf pyrimidine metabolism 
Enzymes: CPSII, carbamoyl phosphate synthetase II; CA, carbonic anhydrase; ATC, aspartate transcarbamoylase; 
DHO, dihydroorotase; DHODH, dihydroorotate dehydrogenase; OPRTase, orotate phosphoribosyl transferase; 
ODC, orotidine 5’-monophosphate decarboxylase; NMPK, nucleoside monophosphate kinase; RNR, 
ribonucleotide reductase; TS, thymidylate synthase; TMPK, thymidylate monophosphate kinase; CTPS, cytosine 
5’-triphosphate synthetase; TK, thymidine kinase; UPRT, uracile phosphoribosyl transferase; and UK, uridine 
kinase. 
Metabolites: UDP, uridine-5’-diphosphate; UTP, uridine-5’-triphosphate; dUDP, 2’-deoxyuridine-5’-diphosphate; 
dUMP, 2’-deoxyuridine-5’-monophosphate; CTP, cytidine-5’-triphosphate; dTMP, 2’-deoxythymidine-5’-
monophosphate; dTTP, 2’-deoxythymidine-5’-triphosphate; dCTP, 2’-deoxycytidine-5’-triphosphate; and CoQ, 
co-enzyme Q. 
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2/ Purine Metabolism 
 Plasmodium species are purine auxotroph parasites that depend exclusively on purine materials 
derived from erythrocytes. Furthermore, as the Plasmodium genome has an extremely high adenine 
content (over 80% AT content), the parasite requires a considerable amount of adenine nucleotides (dATP 
and ATP) to maintain its high replication rate. Erythrocytes are unable to perform de novo purine synthesis 
alone, so the corresponding nucleobases and nucleosides are taken up from the plasma by the erythrocytes 
and then by the parasites.14,15 Purine import from the host cell is mediated by membrane transporters such 
as equilibrative nucleoside transporters (ENTs, Figure 5), Pf ENT1 is the main one from the four 
transporters (Pf ENT1-4) reported to date and supplying the purine salvage pathway.15,16 Although the 
transport of purine and pyrimidine derivatives in mammalian cells is well-documented,17,18 few studies 
have been performed on the parasite transporters in the last decade and mainly concerned Pf ENT1. 
Further investigations are thus required for rational design of purine transport inhibitors as antimalarial 
drugs. 
 A few of the enzymes involved in Pf purine metabolism have attracted special attention, namely 
purine phosphoribosyl transferases (PRT), adenosine deaminases (ADA) and purine nucleoside 
phosphorylases (PNP). Phosphoribosyl transferases induce the ribophosphorylation of purine bases in a 
single step and are present in many parasites, as well as in mammalian cells. In Plasmodium, 
hypoxanthine-guanine-xanthine-phosphoribosyl transferase (HGXPRT) converts hypoxanthine, guanine 
and xanthine into inosine-5’-monophosphate (IMP), guanosine-5’-monophosphate (GMP) and 
xanthosine-5’-monophosphate (XMP), respectively (Figure 6). Purine nucleoside phosphorylases 
degrade nucleosides into their corresponding nucleobases and sugar counterparts (Figure 7). Adenosine 
deaminases convert the exocyclic amino group of purine nucleos(t)ides into their oxo-derivatives (Figure 
8). Moreover, HGXPRT, ADA and PNP enzymes are highly expressed and key players in purine 
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metabolism, but other enzymes are also involved, such as guanosine-5’-monophosphate synthase (GMPS), 
adenylosuccinate synthetase (AdSS), adenosine-5’-monophosphate deaminase (AMPDA) and inosine-5’-
monophosphate dehydrogenase (IMPDH). 
 This metabolism is remarkable because of the few enzymes involved even though it has a crucial 
role in parasite survival. In addition, these enzymes are also present in the metabolic pathway of other 
plasmodial parasites and may have a high degree of similarity. As example PvENT1 shares ∼75% amino 
acid sequence identity with PfENT1.  However, differences between P. vivax and P. falciparum were 
reported and resulted in modifications of the 3D protein structure and/or conformation.19 As example, 
structural differences between Pv and Pf ADA have been highlighted by computational studies and crystal 
structure analysis, and mainly concern the ligand recognition domain.20 
The parasite salvages adenosine from the erythrocytes and the combined action of ADA and PNP 
successively leads to the formation of inosine and hypoxanthine (Figure 4). As very little adenosine is 
available from the erythrocyte (due to the activity of erythrocytic adenosine kinases), the parasite 
essentially relies on hypoxanthine, which is also salvaged from the host. The key purine metabolism 
precursor is consequently hypoxanthine, and therefore malarial cultures are often enriched with this 
nucleobase, which serves as a nutrient to promote parasite growth. Hypoxanthine is then converted into 
IMP by HGXPRT (Figure 4). IMP is thus the nucleotidic precursor of all other purine nucleotides required 
for nucleic acid biosynthesis, especially adenosine 5’-monophosphate (AMP). As Pf does not have the 
genes coding for nucleoside kinases21,22 (AMP synthesis directly from adenosine), there is no other 
alternative to obtain AMP, and IMP is the sole adenosine 5’-monophosphate metabolite available. To a 
lesser extent, it has been shown that by using high concentrations of adenosine in Pf cultures, AMP 
synthesized by RBC could induce erythrocytic AMP uptake into the parasite.22 IMP is also transformed 
into XMP via IMPDH and then into GMP via GMPS. GMP is also produced via a second pathway 
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involving guanosine and guanine uptake, with the latter being PNP and HGXPRT substrates, respectively. 
Similarly, XMP is produced through HGXPRT activity following xanthine uptake.7 
 
Figure 4: Representative scheme of Pf purine metabolism 
In red: main path or nucleic acids synthesis in Pf 
Metabolites: IMP, inosine-5’-monophosphate; XMP, xanthosine-5’-monophosphate; AMP, adenosine-5’-
monophosphate; NDP, nucleoside diphosphate; and NTP, nucleoside triphosphate. 
Enzymes: HGXPRT, hypoxanthine-guanine-xanthine-phosphoribosyl transferase; ADA, adenosine deaminase; 
PNP, purine nucleoside phosphorylase; GMPs, guanosine-5’-mono-phosphate synthase; IMPDH, inosine-5’-
monophosphate dehydrogenase; AMPDA, adenosine-5’-monophosphate deaminase; AdSS, adenylosuccinate 
synthase; and AdSL, adenylosuccinate lyase. 
Transporters: ENT, equilibrative nucleoside transporter, notably Pf ENT1-4. PVM channel are represented at the 
parasitophorus vacuole membrane. 
  
To date, the main strategy developed to inhibit Plasmodium falciparum growth involved targeting PNP 
and ADA Pf enzymes, because of their importance in the hypoxanthine pathway in the parasite. 
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1. Uptake of purine bases and nucleosides into the parasite 
a. Erythrocyte transport pathways 
As for many human cells, mature erythrocytes have a profusion of transport systems (transporters and 
channels) located at the plasma membrane and responsible for the uptake of ions, hexoses, amino acids 
and other nutrients (Figure 5). Human nucleoside transporters (hNTs) thus include various transport 
system families, such as hENT1 and hENT2 (both equilibrative nucleoside transporters and responsible 
for purine and pyrimidine uptake, with nucleosides being the preferred substrates)18, hFNT1 (facilitated 
nucleobase transporter, which transports hypoxanthine and adenine) and hCNTs (concentrative ion-
coupled nucleoside transporters).16,14 It has been demonstrated that hENT1 and hFNT1 are the most 
important source of purine-containing derivatives in Pf-infected RBC, while parasite-induced new 
permeability pathways (NPP, an alteration in membrane permeability) has also been mentioned.23,14 NPP 
are designed to facilitate the uptake of low molecular weight metabolites required for the parasite growth, 
such as sugar, sugar-alcohols, polyamine, nucleosides, nucleobases, ions, amino-acids 24, etc.25,26 
b. Parasite transporters  
Four equilibrative nucleoside transporters (Pf ENT1-4) have been identified to date (Figure 5)—but they 
have yet to be fully characterized—and are expressed during the intraerythrocytic stage of the Plasmodium 
life cycle. 202 According to genetic studies, Pf ENT1 has only 17% identical sequence homology with 
hENT1 and only shares 15 to 22% identical amino acid sequence with other parasite ENT transporters, 
and all four share only 2% similarity between them.16  
Among them, Pf ENT1 (also called Pf NT1) is mainly responsible for the import of most purine 
nucleosides and nucleobases inside the parasite. Its characteristics (affinity and substrate specificity) have 
been the focus of some debate with regard to the model used for transport studies and the effects of purine 
metabolism upon import.27 In 2008, Quashie et al.15 suggested that hypoxanthine and purine nucleoside 
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uptake was mediated by a high-affinity and broad-specificity transporter, i.e. Pf NT1 (located at the 
parasite plasma membrane28), and the existence of another high-affinity transporter and two low-affinity 
systems. Downie and co-workers proposed an alternative model, taking into account the fact that high-
affinity proteins of purine metabolism readily transform Pf ENT substrates into nucleotides.27 They thus 
reported a fast, equilibrative and low-affinity mechanism for Pf NT1.29 Pf ENT1 is a proton-dependent 
transporter30 accepting inosine, hypoxanthine, guanine, adenosine and guanosine as substrates, but with 
higher affinities for hypoxanthine and adenosine (Ki 300-700µM range).31 They are reported to be 11 
transmembrane helix segment proteins, with intracellular N-ter and extracellular C-ter, which is the 
common structure for all protozoan and mammalian ENT1. Helices are mostly linked by short 
hydrophobic connectors, except for two large loops (one extracellular and one intracellular).32 As its 
human homologue, Pf ENT1 may also accept pyrimidine nucleosides as substrate.33 
Pf ENT2 and ENT3 have received much less attention. 16 Pf ENT2 was shown to be located at the 
parasitic endoplasmic reticulum membrane and thus may not be involved in purine uptake.34 Pf ENT3 has 
yet to be localized or shown to be involved in purine or pyrimidine transport.  
Frame et al. have shown that Pf ENT4 is a low-affinity (in the millimolar range) purine transporter 
able to transport both nucleosides and bases such as adenine, adenosine and 2’-deoxyadenosine with low 
affinity.35 Pf ENT4 does not transport AMP or hypoxanthine (the main metabolite in the purine pathway), 
thus presenting a different substrate profile from that of Pf ENT1.  
Like Pf, Pv parasites also present four equilibrative nucleoside transporters. Pv ENT1 shares an 
almost identical amino acid sequence with Pf ENT1, although small differences have been observed with 
variable affinities of both transporters for the same substrate.36 The substrate and inhibitor specificity of 
P. berghei ENT1 has been reported recently.37 
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Figure 5: Main transporters involved in the uptake of purines and derivatives into RBC and the 
parasite.  
PfENT3 is not yet localized; “?” sign, unknown transporters. 
 
2. HGXPRT 
HGXPRT is the most targeted purine metabolism enzyme in P. falciparum due to its major and multiple 
implications in the metabolism of this parasite (Figure 4). The crucial role of HGXPRT in purine 
metabolism has also been observed in P. vivax.38 Indeed, it provides the sole PRT activity for three 
substrates, i.e. converting hypoxanthine, xanthine and guanine into the corresponding nucleoside 5’-
monophosphates (IMP, GMP and XMP). Briefly, HG(X)PRT facilitates transfer of the phosphoribosyl 
moiety from PRib-PP (alpha-D-5-phopshoribosyl-1-pyrophosphate) to 6-oxopurines in the presence of 
divalent metal ions, i.e. usually Mg2+ in vivo (Figure 6). Reyes et al. reported a detailed enzymatic 
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characterization of Pf HGXPRT, demonstrating that phosphoribosyl transferases are the most important 
enzymes in purine metabolism.39  
 
Figure 6: Mechanism and transition state of the 6-oxopurinephosphoribosyltransferase catalyzed 
reaction 
Hx, hypoxanthine; X, xanthine; G, guanine; IMP, inosine 5’-monophosphate; XMP, xanthosine 5’-
monophosphate; GMP, guanosine 5’-monophosphate; α-D-PRib-PP, α-D-ribofuranose-5-phosphate-1-
diphosphate; and PPi, pyrophosphate. 
 
 Few differences between the human and Pf HGXPRT were revealed by Keough et al.40 when 
comparing the specific activity (greater for human enzymes), kinetic parameters and substrate selectivity 
(the human enzyme does not accept xanthine as substrate, contrary to the parasite protein). Both enzymes 
are active as a homotetrameric form and share 44% sequence identity and 76% similarity. Superposition 
of their structures (in the presence of substrates of the catalytic reaction) generates a good root-mean-
square deviation (rmsd) value (nearly 1,7 Å).41 Considering these structural similarities between the two 
enzymes, the challenge is to selectively target and inhibit the parasite phosphoribosyl transferases so as to 
avoid any toxicity for human cells. 
The crystal structures of the human 6-oxopurinephosphoribosyltransferase (Hs HGPRT) in the presence 
of nucleoside analogues have been often described. The human enzyme has three important binding sites 
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hosting the nucleobase (through hydrogen bonds with residues), the 5’-phosphate (binding pocket is 
located between residues 137-141) and the pyrophosphate moiety (of Prib-PP or only PPi). 
 In humans, PRib-PP first binds to the metal ion and then the required nucleobase associates with 
the complex to form the intermediate. Then the pyrophosphate dissociates from the ribooxocarbenium 
complex and nucleoside 5’-monophosphate is released from the enzyme catalytic site.42 The initial 
proposed mechanism for PfHGXPRT was slightly different and consisted of a ping-pong exchange, where 
PRib-PP first binds to the enzyme, followed by PPi release and then nucleobase entry43. These results 
have been contested by the reported crystal structure of PfHGXPRT complexed with 
hypoxanthine.PPi.Mg2+ and a few immucillin transition state analogues.175  It has been shown that 
nucleobase binding is conditional to PRib-PP entry, suggesting that PfHGXPRT proceeds through a 
steady-state-ordered mechanism. 176 
  
3. PNP 
PNP are also important enzymes present in both mammals and protozoan parasites. Like HGXPRT, PNP 
inhibition leads to death of the parasite by blocking the formation of hypoxanthine, a key metabolite of 
the Pf purine metabolism (Figure 4).46,47 Pf PNP is structurally different from the human protein (hexamer 
versus homotrimer and low sequence homology, ~20% identity of the primary amino acid sequence) and 
exhibits different catalytic rates with inosine as substrate (56 s-1 for hPNP and 0.34s-1 for Pf PNP).48–50 
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Figure 7: Mechanism and transition state of the Pf purine nucleoside phosphorylase catalyzed 
reaction 
 
 According to the mechanism proposed by Schramm et al. for both human and Pf PNPs,51,52 the 
nucleoside and phosphate (as nucleophilic participant) first bind to the active site of the enzyme and the 
reaction transforms the inosine/enzyme complex (located on a single active site of the homotrimer), into 
a hypoxanthine/ribose/enzyme complex (Figure 7). Then the enzyme catalyzes cleavage of the glycosidic 
bond to release the ribose-1’-phosphorylated moiety, giving rise to a tight binding hypoxanthine/enzyme 
complex. The latter finally dissociates within the corresponding nucleobase and the D-ribose 
phosphorylated moiety. Both enzymes have similar transition states, with the active site environment being 
more constrained in the parasite enzyme than in the human one (on the basis of different interactions 
between the active site and substrate).  
 
4. ADA 
ADA is a zinc-dependent hydrolase that catalyzes the irreversible hydrolysis of adenosine into inosine, its 
corresponding 6-oxopurine derivative. The reaction is triggered by the deprotonation of a water molecule 
which then reacts with the substrate, giving rise to 6-amino-6-hydroxypurine as intermediate, which 
provides the corresponding oxopurine by releasing one ammonia molecule (Figure 8).53 
 
Figure 8: Mechanism and transition state of the Pf adenosine deaminase catalyzed reaction 
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Human and Pf ADAs are functionally similar and have high sequence homology, but they differ 
slightly in terms of substrate specificity and catalytic turnover. Pf ADA thus accepts both adenosine and 
5’-methylthioadenosine (MTA, a polyamine biosynthesis metabolite) as substrate, which is not the case 
for its human homologue.54  
Pv ADA has been crystallized in a complex with three different ligands (adenosine, guanosine and 2’-
deoxycoformycin, i.e. a known human ADA inhibitor)55. A parasite-specific conformation was observed, 
which closed the substrate binding site within a solvent-less cavity, whereas the human enzyme does not 
close its active site. This difference may explain the recognition of MTA, as the solvent-less cavity hosts 
the hydrophobic thiomethyl group. Amino-acid changes in the active sites of Pv and Pf ADAs have been 
highlighted via computational studies and comparison with a Pf ADA homology model.20  
In addition, P. knowlesi growth (in infected primates) was found to be inhibited by 2’-deoxycoformycin, 
indicating that parasite survival was dependent on adenosine deaminase.56  
In 2017, the Pf proteome was studied to identify commercial drugs which could target and inhibit Pf 
enzymes. Dipyridamole (a nitrogen heterocycle derivative used as blood vessel dilatator) was thus 
reported to be a Pf ADA inhibitor with an IC50 of 30 nM.57 
 
5. IMPDH 
Inosine 5’-monophosphate dehydrogenase catalyzes XMP formation from IMP through a covalent 
mechanism (Figure 9) and serves as an alternative/complementary pathway for providing GMP. As GMP 
synthesis mediated by HGXPRT is not substantial enough to provide the overall amount of GMP required 
for nucleic acid biosynthesis in the parasite, IMPDH inhibition could indirectly and partially block GMP 
formation from XMP.58,59 IMPDH is a homotetramer protein. The active site is located at the C-terminal 
chain, whereas the cofactor (NAD+) binds at another site.60 Consequently, two classes of IMPDH 
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inhibitors can be developed, i.e. one targeting the substrate binding site and the other targeting the cofactor 
binding loops via an uncompetitive mechanism (e.g. mycophenolic acid and phenyl-oxazole urea, 
respectively).61 
Human and Pf IMPDH genome sequences shown only 48% of similar amino acid sequences and exhibit 
differences in the structure of the active site.60 That could possibly help to design selective inhibitors of 
the plasmodial enzyme.  
 
Figure 9: Pf inosine 5’-monophosphate deshydrogenase catalyzed reaction 
 
6. GMPS 
Pf GMP synthetase (belonging to the glutamine amidotransferase family) is a dimeric protein catalyzing 
the irreversible formation of GMP through XMP amination. GMP synthesis via HGXPRT is not enough 
to maintain optimal GMP levels in the parasite,62 thus blocking this enzyme may be a valuable approach 
to inhibit nucleic acid biosynthesis. Pf and human GMPS share 20-30% common chain sequence and both 
contain two domains, i.e. one catalyzing formation of the XMP-adenyl complex (ATPPase), and the other 
providing the required ammonia from glutamine hydrolysis (GATase, glutamine amidotransferase). The 
ammonia molecule is channeled to the other domain in order to generate the GMP product 63 (Figure 10), 
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which is a common amidotransferase reaction step (ping-pong mechanism).62 Both ATPPase and GATase 
sites can be targeted in competitive and uncompetitive ways, respectively. For instance, glutamine 
analogues, such as acivicin and 6-diazo-5-oxo-norleucine (use as antibiotics and known hGMPS 
inhibitors), are able to inactivate the enzyme by covalent modification of the GAT domain.62 Pf GMPS 
also differs with regard to other plasmodial species associated with a single 20 amino-acid long sequence 
located in its GAT domain.63 
 
Figure 10: Formation of GMP from XMP, catalyzed by Pf GMPS from its GAT and ATPPase 
domains 
 
II/ TARGETING PURINE METABOLISM WITH NUCLEOS(T)IDE ANALOGUES  
Because of the importance of purine metabolism for plasmodial parasites, the inhibition of related 
enzymes has been considered since 1984.64 Nucleoside analogues are well-known inhibitors of the nucleic 
acids biosynthesis, so they may also be viewed as potential candidates for targeting of purine metabolism 
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enzymes due to their structural similarities with their substrate. Series of purine-based heterocycles, 
nucleoside and nucleotide analogues have been studied with the aim of targeting these enzymes and related 
transporters. A few of them were designed on the basis of transition state studies. This part of the review 
concerns such compounds as inhibitors of transporters and/or enzymes involved in plasmodial purine 
metabolism. 
 
1. Purine-based Analogues 
In 2006, Keough et al. studied the effects of purine nucleobase skeleton modifications and the ability 
of these derivatives to bind to human and Pf HGXPRT, and the hypothetical discrimination between these 
two enzymes.65 By analogy with 6-mercaptopurines used in cancer chemotherapy66, the proposed 
mechanism of action consists of their conversion—mediated by 6-oxopurinePRTases—into their 
corresponding nucleoside 5’-monophosphate derivatives, thereafter incorporated into DNA or RNA and 
thus interfering with cell replication. Determination of the Km for these derivatives revealed that the 
presence of an exocyclic oxygen-containing group at position-2, and/or a chlorine atom at position-6, 
and/or the replacement of the carbon atom at position-8 by a nitrogen allowed strong discrimination 
between human and Pf HGXPRT. In addition, these nucleobases are able to inhibit P. falciparum in vitro 
growth. The best IC50 values were 1.3 µM and 6.6 µM for 6-mercaptopurine and 8-azaguanine, 
respectively. 
 
2. Nucleoside analogues 
Since natural substrates of the targeted enzymes are mostly nucleosides and derivatives, the easiest 
and most promising way to selectively inhibit them is to design analogues. In the field of antiviral and 
antitumoral chemotherapy, the search for nucleoside analogues has led to the discovery of the active 
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compounds which are nowadays used as drugs. Some of these derivatives were tested against the Pf purine 
salvage pathway, leading to the identification of lead compounds which served as a starting point for the 
synthesis of novel derivatives. 
a. Cordycepin 
Cordycepin (Table 1), an antibiotic and anti-tumoral nucleoside extracted from Cordyceps militari, 
was tested in vitro, by Trigg et al. in 1971 against P. knowlesi and in vivo in P. berghei-infected mice.67 
Effects were noted on in vitro parasite growth at micromolar concentrations, but a full cure was not 
obtained in mice even at high concentration. The fact that nucleic acid biosynthesis in the parasite was 
affected suggested that the purine metabolism of the parasite was targeted.  
b. Mizoribine and ribavirin derivatives 
Mizoribine (Table 1) is an immunosuppressive drug that was isolated from Eupenicillium 
brefeldianum in Japan in 1971. It is clinically used for renal transplantation68 as well as an inhibitor of Hs 
IMPDH in leukemia and viral diseases. Its proposed mechanism of action involves IMPDH inhibition by 
the mizoribine-5’-monophosphate, thus limiting both XMP formation and GMP synthesis mediated by 
GMPS.69 When tested as an antimalarial by Webster and Whaun in 1982, mizoribine appeared to be active 
against drug-resistant Pf strains at 50 µM.70 Variations in the concentration of several purine-containing 
nucleosides and nucleotides in infected RBCs have been studied and a significant decrease was observed 
in the presence of mizoribine. 
Recently, Raza et al. performed virtual screening of a library of ribavirin analogues (Table 1, a base 
modified nucleoside analogue known as a competitive inhibitor of human IMPDH71,72) using a 3D-
homology model of Pf IMPDH.60 Five promising ribavirin derivatives were identified as potential ligands, 
which should be able to selectively target the parasite enzyme by interacting with the active site (hydrogen 
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bonds and hydrophobic pockets). To date, these molecules have not yet been tested in vitro against P. 
falciparum growth. 
Table 1. Representative nucleoside analogues as potential purine metabolism inhibitors 
Cordycepin (3-deoxy-adenosine)67 
 
Inhibitors of Pf IMPDH60,70 
 
 
 
 
Ribavirin derivatives screened by Raza et al.60 
 
Adenosine analogues tested against Pf GMPS by Bhat et al.62 
 
Pyrrolidine nucleoside mono- and bisphosphonates73 
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Tubercidin and derivatives74 
 
Nitrobenzylthionucleosides75 
 
 
c. Psicofuranine and decoyinine 
As psicofuranine and decoyinine (Table 1) were reported to inhibit hGMPS (with 17.3 and 46.5 µM 
IC50 values),76 Baht et al. evaluated them on purified Pf GMPS. They reported a weak inhibitory effect of 
psicofuranine (25% inhibition at 0.5 mM) and no effect of decoynine.62 Only psicofuranine had an IC50 of 
0.3 mM when tested against Pf cultures (3D7 strain).77  
d. PNBPs – Pyrrolidine nucleoside bisphosphonates 
Initially synthesized and tested for their ability to inhibit E. coli, 6-oxopurine 
phosphoribosyltransferases,78 pyrrolidine nucleoside phosphonates (Table 1) were subsequently assessed 
as potential inhibitors of PvHGPRT and PfHGXPRT. The design of such compounds was based on a 
central 5-membered ring skeleton, bearing three substituents anchored through free rotation bonds, thus 
allowing to adopt the best conformation at the active site of the enzyme.73 
In comparison with compound 3, the addition of a second phosphonate tail to the pyrrolidine ring markedly 
decreased the Ki values (from millimolar to nanomolar range) for all three enzymes but to the detriment 
of selectivity. It should be noted that: (i) the nature of the nucleobase did not seem to have a real impact 
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on the activity, (ii) the addition of the hydroxyl group on the second phosphonate tail enhanced the 
inhibitory activity of these derivatives and the stereochemistry had an influence on the affinity of the 
studied enzyme. For instance, the (R)-isomer of compound 1 exhibited a 7.5-fold higher Ki value than that 
of its (S)-isomer on Pv HGPRT. Studies of the crystal structures of the Pv HGPRT-compound 1 complex 
revealed that the oxygen-linked phosphonate tail located within the 5’-phosphate binding pocket could 
explain the difference in Ki observed between the two stereoisomers. Additional interactions also occurred 
between water molecules, the hydroxyl group and the active site for the (S)-isomer of compound 1. 
Structural data regarding the Pf protein are currently not available. 
e. Tubercidins 
The successful use of adenosine analogues in cancer chemotherapy led Coomber et al. to test some of 
them against Plasmodium falciparum. In vitro, the most efficient ones were the 7-deaza-adenosine 
derivatives tubercidin and sangivamycin (Table 1), with IC37 of 0.7 and 0.3 µM (IC37 values are quite 
unusual compared to IC50, but it was used by the authors to compare their results with previously reported 
ones). Their mechanism of action was suggested to be related to purine metabolism, especially with a 
decrease of IMP content in treated Pf-infected erythrocytes.74 In addition, 5-iodotubercidin (a known 
human adenosine kinase inhibitor) has been shown to inhibit Pf growth in vitro (IC50 of 2 µM)22 and 
several tubercidin derivatives appeared to be Pf ENT1 substrates.31 However, no further studies have been 
recently reported in the literature concerning this family of compounds. 
f. NBMPR – nitrobenzylthioinosine 
Nitrobenzylthioinosine (NBMPR) and its guanine analogue (NBTGR) were first assayed as 
antimalarial drugs in 1989 (Table 1).75 In addition to their micromolar IC50 values in Pf-K1 strains (multi-
drug resistant)-infected erythrocytes, they were successfully used in an original approach based on the 
alteration of infected erythrocyte membrane permeability. Briefly, the two derivatives were used to 
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facilitate the uptake of cytotoxic nucleosides (presumably through permeability pathways induced by the 
parasite) into infected erythrocytes, while their ability to selectively inhibit the human transporters 
(hENT1)79 prevented the uptake and further toxic effects in uninfected cells. Later on, it was also proven 
that Pf ENT1 and Pf ENT4 were insensitive to NBMPR.80  
 
3. Transition state analogues as Pf purine metabolism inhibitors 
In theory, a perfect and chemically stable transition state analogue will bind tighter to the enzyme active 
site than the substrate. The protein will enclose the compound with a more thermodynamically stable and 
static conformation, thus preventing natural substrate binding until release of the transition state analogue. 
Moreover, an ideal transition state analogue will be highly selective of the targeted enzyme, avoiding 
toxicity and unwanted side-effects. 
Natural transition state species have a very short longevity and consequently are not directly observable, 
but they can be predicted, or hypothesized, by studying the reaction process mechanisms and determining 
the intrinsic kinetic effects of isotopic compounds. A chemical structure could then be proposed on the 
basis of in silico calculations. Transition state analogues of three parasite enzymes have thus been reported 
to date, i.e. Pf ADA, Pf PNP and Pf HGXPRT.81  
a. Pf ADA inhibition 
 Coformycin and derivatives 
Coformycin and 2’-deoxycoformycin (namely pentostatin) were both known as mammalian ADA 
inhibitors. In 2007, Tyler et al. studied the affinity of these derivatives toward human, bovine and Pf ADAs 
(Table 2) and inhibition constants in the low nanomolar range were observed, but with no specific 
selectivity.82 On the basis of previous results showing that 5’methylthioadenosine or inosine54 were Pf 
ADA substrates, 5’-alkylthio and 5’-phenylthio analogues of coformycin and 2’-deoxycoformycin were 
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synthesized.82 Among them, 5’-methylthio derivatives appeared to be highly selective of the parasite 
enzyme, with Ki of less than 1 nM (Table 2), especially 5’-methylthiocoformycin, which showed >20,000-
fold selectivity for Pf versus Hs ADA. However, no further studies have been reported.  
 L-nucleoside analogues 
In 1995, Upston et al. showed that L-adenosine was significantly transported (via a unique parasite-
induced pathway) and selectively metabolized (through ADA activity) within parasites infected-
erythrocytes.83 These preliminary results led the same team to investigate series of L-nucleoside analogues 
(Table 2).84,85 Among them, L-coformycin and L-isocoformycin were shown to specifically inhibit Pf 
ADA activity in the picomolar range (contrary to their D-isomer, especially 2’-deoxycoformycin, which 
interacted with both human and parasite enzymes).85 L-coformycin, L-isocoformycin and L-sangivamycin 
inhibited the in vitro growth of Pf with an ID50 in the micromolar range.84 
 
Table 2. Nucleoside analogues as Pf ADA inhibitors 
Coformycin and derivatives as inhibitors of human and plasmodic adenosine deaminases82 
 
Ki* values correspond to the equilibrium dissociation constant upon completion, after a slow onset, for tight 
binding inhibition of the enzyme (consequent upon a time-dependent conformational change in the enzyme 
that improve the binding after a moment, thus Ki* is lower than Ki) reported for transition state-analogues. 
Compounds with Ki* values are called slow-onset tight binding inhibitors. Ki values of >10,000 indicate that 
assays with 10 µM concentration of the compound showed no inhibition under the assay conditions 
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L-nucleoside derivatives as PfADA inhibitors84,85 
 
Dimers with L-nucleosides as carrier for cytotoxic D-nucleosides25 
 
 
Gero et al. took advantage of the ability of some L-nucleosides to be selectively transported into 
infected erythrocytes and proposed dinucleoside monophosphate prodrugs (Table 2) that combined a L-
nucleoside as carrier and a cytotoxic nucleoside as antimalarial agent.25 The release mechanism involved 
the cleavage of the 3’-5’ phosphodiester linkage, delivering the free 3’-OH L-nucleoside and the 5’-
monophosphate D-nucleoside (the position of the phosphate moiety, 3’- or 5’- inside the targeted cell, was 
shown to be crucial for the activity. The best results were obtained for dinucleotides containing 5-fluoro-
2’-D-deoxyuridine (FUdR) as cytotoxic nucleoside and 2’-deoxy-L-adenosine or L-adenosine as carriers, 
with in vitro antimalarial activities in the low micromolar range. No further information is currently 
available.  
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b. Pf PNP Inhibition 
 First generation: immucillins 
In 1966, Reist et al. first synthesized an adenosine analogue in which the sugar ring oxygen was replaced 
by a nitrogen.86 In 1998, studies on bovine PNP transition states led Miles et al. to design immucillin-H 
(Imm-H) and immucillin-G (Imm-G), as analogues of the proposed riboxocarbenium ion transition state.87 
These compounds are iminoribitol C-glycoside derivatives incorporating an iminoribitol sugar scaffold 
and 9-deazapurines. Replacement of the labile glycosidic bond by a C-N link led to a stable analogue with 
increased pKa values for the nucleobase N7 atom (Figure 11). Tight binding constants, in the picomolar 
range, were determined for these two immucillins on bovine and human PNP. 
 
Figure 11: Common structure of first-generation immucillins 
 
In 2002, Imm-H, Imm-G and analogues were evaluated as PfPNP inhibitors (Table 3)48 and Imm-H was 
also shown to be able to kill parasites in culture experiments, with an IC50 of 63 nM (3D7 strain).54 But 
these immucillin derivatives were first designed as substrates of human PNP and exhibited low to modest 
selectivity for parasite PNPs, which is a crucial point for the development of antimalarial immucillins. As 
the structures of the Pf PNP-ImmH complex revealed that the enzyme could accept 5’-substitued 
nucleosides,49 5’-methylthioimmucillin (MT-ImmH) was designed to selectively target the parasite 
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enzyme. 5’-MT-ImmH inhibited both human and Pf PNP in infected erythrocyte cultures and selectively 
bound to the Pf enzyme according to the Ki values (Table 3). Later, it was also demonstrated that MT-
ImmH was able to kill Pf in cultures, with an IC50 of 50 nM (3D7 strain).54 Other immucillin analogues 
(e.g. 2’-deoxy-Imm, 8-aza or fluorinated purine, 6-methoxy or thiopurine, 5’-acid or amide-Imm, ara-Imm, 
etc.) were reported by Lewandowicz et al., but they all exhibited higher binding affinity for human 
protein.88 Overall, these studies highlighted that the 5'-methylthiosubstitution resulted in a unique Pf PNP 
substrate specificity, as observed for MT-ImmH. 
 
Table 3. Transition state analogues as Pf PNP inhibitors 
 Immucillins and methylthioimmucillin (ND: not determined) 48,49 
 
 Second-generation immucillin derivatives88  
 
These compounds are represented in neutral form, but the nitrogen is protonated at physiological pH 
thus mimicking the cation of the transition state. No slow-onset tight binding inhibition was observed 
for Pf PNP 
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Fluorinated second-generation immucillins89 
 
Third-generation immucillin derivatives90,91 
  
The complete iminoribitol ring shown in red 
 
The intact iminoribitol ring is shown in red 
L-enantiomers of potent immucillins92 
 
 
 Second generation immucillins: N1-branched analogues 
To overcome the expensive and complex synthesis of these immucillins, the development of a second 
generation of Imm derivatives was considered while focusing on easier synthetic pathways. The latter 
initiatives generally involved the displacement nitrogen close to the C1’ position on the iminoribitol ring 
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to mimic the PNP transition state. This modification nevertheless requires removal of the 2’-hydroxy 
group to avoid the formation of an unstable hemiaminal scaffold and to eliminate one asymmetric carbon. 
On the basis of a structural analysis and theoretical calculations, Schramm’s group proposed DADMe-
immucillin-H (4’-deaza-1’-aza-2’-deoxy-1’-(9-methylene)-immucillin-H, derivatives (Table 3), where 
the introduction of a methylene bridge between the sugar residue and 9-deazahypoxanthine allows the 
leaving group to be more distant from the oxacarbenium ion mimic than in Imm-H.52 
DADMe-immucillin-H (BCX-3408) and DADMe-immucillin-G (4’-deaza-1’-aza-2’-deoxy-1’-(9-
methylene)-immucillin-G, BCX4945) (Table 3) have been identified as potent human PNP inhibitors 
(with picomolar Ki* values)93 since 2003 while exhibiting lower affinities for Pf PNP. 88 Despite this, 
DADMe-immucillin-G has been shown to completely inhibit Pf PNP and suppress P. falciparum 
development in Aotus primates,94 but no further development has been reported to date. 
Many immucillin derivatives have been proposed and studied (fluorinated, N-alkylated, 5’H, 5’-
thiophenol, 5’-carboxylic acids, etc.) to revert the selectivity of these derivatives toward the Pf enzyme, 
but they preferentially bound to Hs PNP rather than Pf PNP (Table 3).88,89  
Second and first generation immucillins and transition state studies on bovine, human and malarial 
PNPs were reviewed by Schramm in 2005.95 
In 2010, Cui et al. proposed novel N-branched immucillin derivatives where the purine base was 
replaced by uracil, as uridine was reported to be a PNP substrate, including variations in the linker length 
between the base and the pyrrolidine ring.96 Modest affinities for Pf PNP were determined for uracil-based 
transition state analogues (Ki in the micromolar range), and no significant antiparasitic activity was 
observed in vitro.  
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 Third generation immucillins: Acyclic analogues 
As a continuation of their research program on transition state analogues as PNP inhibitors, Schramm’s 
group designed third generation acyclic immucillin derivatives by cleaving the iminoribitol ring, which 
led to iminoalcohol chains linked to 9-deazapurine 90, or by replacing the pyrrolidine ring by a serinol 
chain.91 The flexibility of the acyclic scaffold allowed the chain to rotate freely inside the active site, 
possibly enhancing the positioning of the compound. In addition, these compounds were easier to 
synthesized while using cheaper precursors. Only the acyclic iminoalcohol series was assessed against 
both human and Pf PNPs, and all compounds exhibited better selectivity for human protein. The best Kd 
value for the human enzyme was reported for the imino-tri-alcohol DATMe-Imm-H (Table 3). Pf PNP 
thus seemed to be more selective for the ribose ring than its human homologue, and consequently 
DADMe-immucillins and immucillins are still the best compounds in this series to date. 
 L-nucleosides 
Several studies carried out on L-enantiomers of known biologically active nucleoside analogues have 
highlighted the importance of isometry and the potential of L-nucleosides.97–99 Based on these 
observations, Clinch et al. synthesized and compared D-immucillins (Table 3) to their L- enantiomers 
against human and Pf PNPs (Table 3).92 All L-analogues were less potent than their D-enantiomers against 
malarial and human protein, while showing nanomolar range inhibition. No selectivity towards Pf 
enzymes was reported.  
c. Pf HGXPRT Inhibition 
 In 1999, Li et al. hypothesized that known transition state inhibitors of PNPs could also mimic 
HGPRT (human enzyme) and HGXPRT ribooxocarbenium species after phosphorylation of the 5’-
hydroxyl of the nucleoside analogue.100 The nitrogen atom replacing the intracyclic oxygen of ribose in 
immucillins can provide a cation which may serve as the ribocation transition state of the enzyme. 5’-
33 
 
monophosphate derivatives of immucillinH and immucillinG (Figure 12: Comparative affinities of 5’-
phosphate immucillin derivatives for Hs HGPRT and Pf HGXPRT) were thus synthesized and 
evaluated towards Pf and human HG(X)PRT, and the two compounds were found to exhibit similar 
affinities to both proteins in the low nanomolar range. Immucillin 5’-monophosphate derivatives were not 
further investigated due to their susceptibility to phosphates present in biological media. 
 
Figure 12: Comparative affinities of 5’-phosphate immucillin derivatives for Hs HGPRT and Pf 
HGXPRT 
 
In 2012, Hazleton et al. reported the synthesis and biological assessment findings of a second generation 
of immucillin-5’-monophosphate analogues belonging to the acyclic phosphonate family. In this review, 
these derivatives are part of the aza-ANPs section.101 Briefly, acyclic immucillin phosphonates (AIPs) 
were the first compounds to show tight binding inhibition of Pf (with Ki in the nanomolar range) and 
human (with Ki in the micromolar range) phosphoribosyl transferases, thus good selectivity for the parasite 
protein was observed.  
d. Conclusion on immucillins and transition state analogues 
The use of transition state analogues has been successful in inhibiting PNP, ADA and HGXPRT. A 
wide variety of structures, mainly based on the immucillin skeleton (four generations developed through 
the years), have been synthesized along with studies on the purified enzymes. One of their limitations is 
their lack of selectivity regarding human and parasite enzymes, and their entry into the parasite may also 
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be problematic due to their high polarity. To our knowledge, the mechanism of their uptake into parasites 
does not involve Pf ENT1 transporters.31 In 2012, Frame et al. demonstrated that immucillin and DADMe-
immucillins were recognized by Pf ENT4,35 suggesting the possible role of this transporter in the uptake 
of these compounds into the parasite  
The fourth generation of immucillins designed as human PNP transition state analogues were reviewed 
by Ho et al. in 2007.102 DADMe-immucillin-G was under preclinical development for malaria treatment 
in 2011,94 but the data are currently unavailable. Finally, as for all known antimalarial treatments, 
Plasmodium falciparum has developed genetic drug resistance (gene amplification and drug-binding 
mutations of Pf PNP gene) to PNP inhibition by DADMe-Imm-G, as recently demonstrated by Ducati et 
al.103 
 
4. Nucleotide analogues: the acyclic nucleoside phosphonate family 
a. Introduction to acyclic nucleoside phosphonate derivatives 
Since the 1960s, nucleoside analogues have been proposed as antiproliferative agents based on 
their ability to interfere (as their 5’-triphosphate derivatives) with the last steps of nucleic acid biosynthesis. 
Extensive modification of the nucleobase and/or sugar moiety was carried out to enhance their efficacy. 
In 1978, A. Holy and E. De Clercq described the broad spectrum antiviral activity of a new family of 
nucleoside analogues consisting of a simple aliphatic chain linked to a nucleobase, i.e. (S)-DHPA ( (S)-9-
(2,3-dihydroxypropyl)adenine, also known as Duviragel®, (Figure 13: First acyclic nucleoside and 
nucleoside phosphonate analogues designed).104 A few months earlier, G. Elion had reported a new 
antiherpetic agent, another acyclic nucleoside analogue,105 i.e. 9-(2-hydroxyethoxymethyl)guanine, 
currently known as acyclovir (Figure 13: First acyclic nucleoside and nucleoside phosphonate 
analogues designed) and in 1988 she shared the Nobel Prize with G. H. Hitchings and Sir J. Black for 
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this discovery. Studies on the antiviral potential of phosphonoacetic acid, with the aim of developing 
isopolar and catabolically stable nucleotide analogues, gave rise to the design of the first acyclic 
nucleoside phosphonate (ANP) in 1986 by Holy et al, i.e. (S)-HPMPA or ((S)-9-(3-hydroxy-2-
phosphonomethoxy-propyl)adenine) (Figure 13). The latter was described as a nucleotide analogue 
resistant to phosphoesterase hydrolysis due to the presence of the phosphonate moiety (P-C bond) and an 
acyclic chain replacing the sugar ring, and it was found to be active against anti-DNA viruses.106 
Meanwhile, the antiviral activity of 2-(phosphonomethoxy)ethyl-adenine (PMEA) was also reported.107 
(S)-HPMPC (cidofovir) was the first ANP marketed (in 1996) for cytomegalovirus retinitis treatment. 
Over the last three decades, many ANPs have been designed, synthesized and evaluated against viruses 
(cytomegalovirus, hepatitis B and HIV), and they still represent a promising and efficient family of 
drugs.108,109 
 
Figure 13: First acyclic nucleoside and nucleoside phosphonate analogues designed 
 
Due to their negative charge and relatively small structure, phosphonate derivatives are too polar to easily 
cross cell membranes, except by endocytosis. Infected erythrocytes, like normal RBCs, are not able to 
undergo endocytosis.110 The drug therefore must reach the intracellular parasite by successively crossing 
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erythrocyte, parasitophorous vacuole and parasite membranes. Consequently the use of prodrugs to 
enhance the lipophilicity of the drug by hiding charges and/or adding long aliphatic tails is essential to 
increase cell uptake and the overall bioavailability of these derivatives.111,112 These temporary 
phosphonate moiety protecting groups, once within the parasite or RBC, are cleaved to release the parent 
drug and eventually limit possible side-effects before delivery.  
Prodrug approaches have been successfully applied to ANPs in antiviral chemotherapy, including 
adefovir dipivoxil (Hepsera®, approved in 2002 for chronic HBV infection treatment) and tenofovir 
disoproxil fumarate (Viread®, approved in 2001 for HIV infection treatment).113,114  
b. Standard acyclic nucleoside phosphonates 
 Based on the success of ANPs in chemotherapeutic treatment of DNA virus infections, several 
groups have assessed their potential for treating other diseases, namely in protozoan infections like malaria. 
In this respect, (S)-HPMPA, (S)-3-deaza HPMPA and (S)-HPMPADAP (2,6-diaminopurine) were first 
tested in 1991 against Pf and P. berghei infected RBCs (Figure 14). S-HPMPA is active in vitro against 
Pf at nanomolar concentration, which is more than 1,000-fold less than the cytotoxic dose for human cells. 
115 When evaluated in P. berghei infected mice, four injections of 20 mg/kg HPMPA at 3-day intervals 
decreases parasitemia to low detectable levels but does not lead to a complete cure.115 Using extracted 
plasmodial DNA polymerases, the inhibitory activity of these compounds was also observed and 
interference with the replication process was hypothesized. Unfortunately, the effects of (S)-HPMPA in Pf 
infected mice were hampered by nephrotoxicity and hepatotoxicity as well as the limited half-life in 
plasma.116 
In 1999, Smeijsters et al. conducted an in vitro study of 48 ANPs belonging to five main structural groups 
with the aim of inhibiting plasmodial DNA polymerase activity (Figure 14).117 All HPMPA derivatives 
(except (S)-HPMPA and (S)-3-deaza-HPMPA) exhibited antiplasmodial activity in the micromolar range. 
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(S)-HPMPA was found to be less potent (0.18 µM) than reported by de Vries et al. due to the use of a 
different IC50 determination method. One of the most interesting results was the difference in IC50 between 
the two isomers of HPMPA and 3-deaza-HPMPA. Indeed, (R)-enantiomers of both compounds were less 
potent than the (S)-enantiomers. This was attributed to the fact that kinases may not be able to recognize 
(R)-enantiomers of phosphorylated substrates. 
Conversely, PMEA derivatives had no significant activity, presumably due to the lack of the hydroxyl 
group present in the HPMPA derivatives. Studies on hydrogenated and fluorinated ((S)-FPMPA) 
derivatives revealed no inhibition, thus confirming the previous hypothesis. However, the difference in 
antimalarial activity observed between PMEA (IC50> 250 µM) and its prodrugs bis(POM)PMEA (IC50 = 
37.3 µM) was significant. As the prodrug is more lipophilic and neutral than PMEA, the improved activity 
could be explained by the efficient prodrug uptake through the host cell and parasite membranes. 
Modification of the nucleobase counterpart with similar phosphonate tail was then envisaged. (S)-HPMPG 
exhibited a similar antimalarial activity of about 4 µM, as well as 2-chloroadenine, 2,6-diaminopurine, 7-
deazaadenine HPMP compounds, whereas 2-aminomethyladenine, 2-aminomethylhypoxanthine or 2-
methylthioadenine derivatives did not exhibit any activity at 100 µM.117 The nature of the nucleobase and 
the presence of the phosphonate moiety thus seemed to be crucial as non-phosphorylated compounds 
(acyclic nucleoside) were inactive. For the latter, either the lack of appropriate kinases in Plasmodium 
limits their transformation into active form and/or their polarity prevents their passive passage through the 
membranes. 
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Figure 14: IC50 of several ether ANPs in Pf-infected RBCs (from Smeijsters et al.) 
Obviously these compounds could target any enzymes involved in nucleic acid metabolism pathways, but 
Smeijsters et al. focused on the potency of ANPs to inhibit DNA replication (because (S)-HPMPA has 
been described as a viral DNA polymerase inhibitor) but did not envisage any other possibilities. Note 
also that pyrimidine-containing ANPs, such as (S)-HPMPU, (S)-HPMPT and (S)-HPMPC, did not show 
any parasite growth inhibition.117 
In conclusion, this pioneer work highlighted the antimalarial potency of ANPs and the importance of the 
nature of the nucleobase and the stereochemistry for in vitro antiplasmodial activity, as well as the possible 
passive uptake of these drugs when the corresponding prodrugs were used. 
In 2009, Keough et al. reported, for the first time, novel series of ANPs to target Pf HGXPRT.118 These 
authors performed an SAR study to compare the length and position of the oxygen atom within the 
phosphonate tail (e.g. cyclic-3-hydroxy-2-(phosphonomethoxy)-propyl (cyclic-HPMP), 2-
(phosphonoethoxy)ethyl (PEE), 2-(phosphonomethoxy)ethyl (PME), 3-fluoro-2-(phosphono-
methoxy)propyl (FPMP), 2-(phosphonomethoxy)propyl (PMP), etc., (Figure 15: Inhibition constants of 
two series (C4 and C5) of ether ANPs on parasite and human 6-oxopurine PRTs) and the nature of 
the nucleobase on the affinity for Pf and human enzymes, and selectivity toward the parasite protein. A 
comparison of several PME analogues revealed that the nature of the nucleobase had a crucial effect on 
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binding to the human HGPR catalytic site. The best tradeoff in terms of affinity (Ki in the low micromolar 
range) and selectivity was found to be the combination of a PEE tail and a 8-substituted guanine as 
nucleobase (i.e. 8-azaguanine, etc.). Selected derivatives were tested in vitro and were found to be able to 
inhibit the Pf growth, with IC50 values in the micromolar range (Figure 15).118 
 
 
Figure 15: Inhibition constants of two series (C4 and C5) of ether ANPs on parasite and human 6-
oxopurine PRTs 
 
In the absence of any crystallized Pf HGXPRT with the studied ANPs, human HGPRT complexes were 
used as models in structural studies and highlighted that the loop hosting the phosphonate or phosphate 
group seemed to be identical for both enzymes.118 The three oxygen atoms of the phosphonate group 
makes hydrogen bonds with the protein, whereas the natural substrate (GMP) has fewer hydrogen bonds, 
indicating that the phosphonate group is essential for tight binding at the active site while not being 
involved in any selectivity contribution. According to docking studies, the purine ring of ANPs binds at 
the nucleobase binding site of the enzyme. These results pave the way for the development of ANPs 
targeting HGXPRT, based on the fact that the potency of this family was found to inhibit Pf growth in 
vitro and on findings regarding their interaction within the active site of the enzyme. 
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Meanwhile, these authors also reported the synthesis of 43 α- and β-substituted PEE derivatives bearing 
guanine and hypoxanthine (Figure 16: Structure of α- and β- branched 2-(phosphonoethoxy)ethyl 
ANPs) and their inhibitory activity against Pf and human HG(X)PRT was determined.119 Overall, α-
substituted (R1=methyl or ethyl) phosphonate derivatives were either non-active or weakly active against 
both enzymes and it was suggested that these results were due to steric hindrance. 
 
Figure 16: Structure of α- and β- branched 2-(phosphonoethoxy)ethyl ANPs 
 
The study of β-branched ANPs revealed inhibition of both enzymes (Figure 17: Inhibitory activities of 
β- branched PEE ANPs on human HGPRT and Pf HGXPRT) in the micromolar range, but with low 
to reverse selectivity, with the natural nucleobases being preferred. The smallest substituents better 
accommodated the active site, and the absence of binding of a β-benzyl-substituted ANP was confirmed. 
It was hypothesized that the presence of substituents hampers proper closure of the loop in Pf HGXPRT. 
 
Figure 17: Inhibitory activities of β- branched PEE ANPs on human HGPRT and Pf HGXPRT 
 
Similarly, Cesnek et al. synthesized series of 9-phosphonoalkyl and 9-phosphonoalkoxyalkyl purines and 
tested them on human and Pv HGPRT, and on Pf HGXPRT (Figure 18: Studies of the impact of the 
chain length of ANPs on their inhibitory activities against Pf, Pv and human 6-oxopurinePRT).120 
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The optimal number of atoms within the linker thus seemed to be four or five, compounds with six atoms 
or more being highly selective for human HGPRT. This latter enzyme appears to be able to host longer 
derivatives than the parasite enzyme. The presence of an oxygen atom within the four-atom linker was 
mandatory for interfering with parasite proteins, indicating that the oxygen in the ribose ring may be 
responsible for important binding site interactions. As previously observed, guanine is apparently the 
preferred nucleobase and all modified nucleobases (2-amino-6-chloropurine, 6-bromopurine, etc.) lead to 
derivatives with weaker inhibitory activities (Ki values above 100 µM). This indicates that efficient 
binding of both the phosphonate group and the nucleobase is essential at the catalytic site to obtain optimal 
Ki values. In conclusion, at least a four carbon atom chain length and a guanine as nucleobase were 
required for significant inhibition of these proteins, but with low or no selectivity towards parasite proteins, 
while the presence of an oxygen atom in the linker was somewhat favorable. 
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Figure 18: Studies of the impact of the chain length of ANPs on their inhibitory activities against 
Pf, Pv and human 6-oxopurinePRTs 
 
Based on results on PEE derivatives, Krecmerova et al. proposed to study the effect of the insertion into 
the phosphonomethoxypropyl chain of a polar group (an hydroxyl or a carboxyl) at the β-position related 
to the nucleobase (Figure 19).121 These new derivatives, which incorporated a small polar or anionic side 
chain, were less efficient but presented some selectivity for Pf and Pv enzymes. These derivatives were 
all tested as racemic mixtures, so the impacts of stereoisomery could not be determined. 
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Figure 19: Representatives of PMP ANPs 
 
  In 2015, on the basis of the results obtained for the HPMP series (Figure 14) and computational 
studies, novel analogues bearing side chains in the -position related to the nucleobase were designed 
(Figure 20), including (S)-2-(phosphonoethoxy)propanoic acid (CPEE), (S)-3-hydroxy-2-
(phosphonoethoxy)propyl (HPEP) and (S)-2-(phosphonomethoxy)propanoic acid (CPME).122 Biological 
studies on Pf and human PRT enzymes revealed that CPME analogues were inactive, in agreement with 
the fact that a five-atom chain is optimal for tight interactions at the active site.123,124 Concerning HPEP 
derivatives, again the nature of the nucleobase was found to be crucial as only the 8-bromoguanine, 
guanine and hypoxanthine analogues showed some affinity (with Ki in the low micromolar range), but 
only the guanine HPEP ANP presented a 6-fold better selectivity for the parasite enzyme. CPEE 
derivatives exhibited similar activities against both enzymes, and in this case only the hypoxanthine 
derivatives appeared to be more selective for Pf HGXPRT than for human HGPRT. Finally, the presence 
of an acidic, ester or hydroxyl group as side chain did not lead to a significant difference between these 
three series of compounds. The crystal structures of HPEPG and HPEPHx revealed that residues located 
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in the vicinity of the active site were flexible and mobile, and the activity enhancement was hypothesized 
to be associated with the ‘locking’ of these residues (tighter binding). 
 
Figure 20: HPEP and CPEE ANPs and their corresponding prodrugs  
R1, HPEP or CPEE side-chain; R2, H or NH2. 
 
In order to facilitate cell uptake, phosphorobisamidate prodrugs incorporating L-phenylalanyl moieties 
(Figure 20: HPEP and CPEE ANPs and their corresponding prodrugs ) were prepared and assessed 
in vitro in Pf strains W2 and D6.122 Mono-substituted phosphorobisamidates did not exhibit significant 
antimalarial activity, probably due to the fact that the free amino group may not be easily hydrolyzed in 
cells. IC50 values of di-substituted phosphoramidate prodrugs ranged from 22 to 103 µM.  
c. Bisphosphonates ANPs - ANbPs 
On the basis of an analysis of the crystal structure of human HGPRT complexed with PEEG 
analogues, new series of ANPs containing a second oxymethylphosphonate group and increased flexibility 
of the two phosphonate tails were designed (Figure 21).125 Most of the compounds had Ki values in the 
sub-micromolar range, but little selectivity towards Pf HG(X)PRT was observed. Inhibitory activity 
against the parasite enzyme was noted when the oxygen atom of the phosphonate tail was moved from 
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position 4 to 3. The position of the oxygen atom may thus modify the chain conformation while enhancing 
its binding at the active site. Studies on the crystal structure of human HGPRT complexed with the first 
derivative of Figure 21 revealed that the second phosphonate group interacted with amino acid residues 
via Mg2+ ion, thus highlighting the contribution of this group in comparison to PEEG analogues. Docking 
studies also revealed that the second phosphonate group was located near the PPi binding site but did not 
share interactions inside this pocket. 
 
Figure 21: Bisphosphonate ANPs tested on human and malarial 6-oxopurinePRTs 
 
Two types of prodrug were proposed to increase the cell permeability of parent ANPs. The negative 
charges of PEEG (Figure 15) were either masked by one or two lipophilic chains (Figure 22), or as a bis 
phosphoramidate including an alanine ethyl ester. In comparison to the parent drug (PEEG, IC50 242 µM 
on Pf strain D6), the presence of two substituents decreased the biological activity (IC50 56 µM) and the 
best result was obtained for the prodrug that included a single hexadecyloxypropyl chain (7.6 µM)125, a 
behavior that had already been noted with antiviral compounds.126 For ANbPs (Figure 22), ethyl L-
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phenylalanyl (instead of alanyl) moieties were envisaged for phosphorobisamidate prodrugs with the aim 
of further increasing the lipophilicity of the final compounds. In vitro evaluation of these three prodrugs 
on Pf strains D6 and W2 led to similar results, with IC50 values in the low micromolar range.125 Note that 
some cytotoxicity on mammalian cells was observed for the lipophilic monoester PEEG prodrug (~36-61 
µM CC50 on all three human cell lines tested) as well as for bisphosphonate prodrugs (~41-130 µM 
CC50).125 
 
Figure 22: Biological assessment of ANbP prodrugs on Pf strains 
 
In 2017, Spacek et al. proposed novel series of ANbPs derivatives (Figure 23) rationally designed on the 
basis of the crystal structure of the previous ANbP lead compound (Figure 21) complexed with human 
HGPRT and based on molecular docking studies, suggesting that increasing the length of the phosphonate 
tail by one atom could allow its location in the PPi binding pocket.127 Various nucleobase modifications 
showed that hypoxanthine (compound 7), 8-bromoguanine (compounds 5 and 8) and 7-deazapurine 
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(compound 6) derivatives were equally or less active than the guanine derivative (compound 4, Figure 
23). Adding one carbon atom into the phosphonate chain (Figure 23, compound 4) led to a 10-fold 
decrease in the Ki values on the human enzyme (0.006 µM to 0.03 µM) but had no effect on Pf HGXPRT 
(Ki = 0.07 µM). For this latter derivative, a crystal structure was obtained in a complex with human 
HGPRT and the affinity gain was associated with the location of the second phosphonate chain within the 
PPi binding site, whereas the phosphonate tail of the previous derivative was too short to reach this site 
and share interactions. They also showed that this new compound bonded strongly in the active site 
through a network of hydrogen bonds between protein residues, phosphonyl oxygen atoms and 
magnesium ions. Finally, phenylalanine phosphoramidate prodrugs were synthesized and their 
antimalarial and cytotoxicity activities were determined. Most of them exhibited IC50 values in the 
micromolar range against D6 and W2 Pf strains, and prodrugs of the best ANbPs in this series exhibited 
low cytotoxicity compared to the others (CC50 212 µM on human lung carcinoma cells).  
 
Figure 23: Novel ANbPs designed by Spacek et al. to study the impact of the phosphonate chain 
and nucleobase modifications on PRTase inhibition 
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d. Fluorinated ANPs 
In addition to the previously reported ANPs,149,119 a fluoromethyl group was incorporated as 
substituent at the beta-position related to the nucleobase on the basis of the PEE and PME scaffolds, giving 
rise to 3-fluoro-(2-phosphonoethoxy)propyl (FPEP) and 3-fluoro-(2-phosphonomethoxy) propyl (FPMP) 
derivatives, which were obtained as pure isomers (Figure 24).124 
 
Figure 24: Fluorinated ANPs and their biological activities 
 
 Briefly, FPMP derivatives were found to be very weak inhibitors (Ki >50 µM) of the three enzymes, 
except for the (S)-isomer incorporating hypoxanthine which exhibited a Ki of 13 µM toward Pf HGXPRT. 
Among the FPEP series, the guanine analogues exhibited inhibition constants in the low micromolar range 
for the three enzymes, with no significant selectivity for the parasite enzymes (Figure 24). No FPEP and 
FPMP derivatives were more active than PEEHx and PEEG ANPs. 
Molecular docking demonstrated that the fluoromethyl group was too small to interact significantly with 
protein residues at the active site, thus not really reflecting any effect of the fluorinated group on the 
activity. One interesting finding was the effect of stereoisomery, (S)- and (R)-isomers providing different 
profiles, as previously noted by other authors. Docking studies revealed different positioning of the 
nucleobase for each isomer, with one being closest to the aromatic ring of residue F186. The 
stereochemistry also influenced the position of the phosphonate group within the 5’-phosphate group loop, 
thus affecting the activity. Indeed, the binding of this group is one of the most crucial for the affinity.124 
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e. Acyclic immucillin phosphonates (AIP) 
In 2012, Schramm and co-workers concluded from their preliminary studies on immucillin 5’-
monophosphate derivatives that they were unable to act efficiently as antimalarials in vitro due to 
hydrolysis of the 5’-phosphate group by cellular phosphatases.101 As an alternative and inspired by the 
work done on ANPs, they designed acyclic immucillin phosphonate derivatives (AIPs, Figure 25), by 
cleaving the sugar moiety of immucillin derivatives and replacing the 5’-phosphate group by a hydrolysis-
resistant phosphonate bond and investigated them as potential PRTase inhibitors.101,123 
 
Figure 25: First AIPs tested to inhibit Pf HGXPRT and Hs HGPRT activities 
 
Pf enzymes were found to be remarkably selective for all derivatives (SI >350). The most potent 
compounds included a hydroxymethyl group as side chain, with sub-nanomolar Ki values (Figure 25, 
compounds 12-14). The most surprising result was the increased selectivity observed when a phosphate 
group linked to a serinol-like chain replaced the phosphonate tail (compound 14). The introduction of 
fluorine atom(s) in the α-position related to the phosphorus atom (compound 13) was envisaged so that 
phosphonate would mimic the pKa of a phosphate group, but this modification did not improve Ki values 
towards Pf and human PRTases.123 
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f. Aza-ANPs 
 In 2012, novel ANP analogues, where a nitrogen atom replaced the oxygen atom within the parent 
PEE scaffold, were compared for their ability to inhibit Pf HGXPRT, with the aim of introducing a novel 
class of nitrogen-containing ANPs (Figure 26)128 This modification led to less active derivatives and 
increased the affinity for the human enzyme (reversed selectivity). These negative effects on the activity 
and selectivity may be attributed to the ability of the secondary amino group to protonate at physiological 
pH, thus modifying the chain conformation (confirmed by docking studies).128 
 
Figure 26: Comparison the inhibitory activity of oxygen- and nitrogen-containing ANPs 
derivatives 
 
Then, N-branched ANPs including a second chain linked to the nitrogen atom were synthesized, thus 
leading to a tertiary amine at the core of the compounds (Figure 27: Evaluation of N-branched ANP 
potent inhibitors of malarial and human 6-oxopurinePRTs).128 The side chains were found to have 
various functionalities such as cyano- (compounds 15-16), hydroxy- (compound 17), methyl ester- 
(compounds 18-19) and carboxylic acids (compounds 20-21), as shown in Figure 27. In all cases, 
guanosine derivatives exhibited better affinity for the human enzyme than for the parasite enzyme, 
whereas some hypoxanthine derivatives exhibited sub-micromolar affinity and significant selectivity for 
the Pf protein. Cyano- and hydroxy-substituted aza-ANPs showed better affinity for the human enzyme. 
All compounds showed weak potency towards parasite enzymes. Finally, promising results were obtained 
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when the second tail had a length of three carbon atoms and included a carboxylic acid or a methyl ester 
group (compounds 19-20).  
Docking studies on these compounds were also performed with human HGPRT to support the biological 
results. The functional group is supposed to be located in a hydrophobic pocket differing from the PPi 
binding site. In the case of the hydroxyl compound, the -OH group is supposedly bound through hydrogen 
bonds to the internal phosphonate, thus hampering it from occupying the 5’-phosphate bonding pocket. 
The nature of the linker has a marked impact on the location of the second group within the active site, 
e.g. in the case of the two cyano compounds 15 and 16, thus lowering the affinity.  
 
Figure 27: Evaluation of N-branched ANP potent inhibitors of malarial and human 6-
oxopurinePRTs 
 
Prodrugs (Figure 28) of the previously described aza-cyano ANPs were subsequently synthesized in order 
to perform cell culture experiments against Pf strains.129 As expected, the use of bisamidate and diester 
prodrugs led to a potency gain in comparison to the parent compounds. However, some cytotoxicity was 
observed for the guanine derivatives, presumably due to the higher affinity of this ANP for the human 
protein, contrary to the hypoxanthine-containing prodrug. 
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Figure 28: Cyano-aza-ANPs and prodrugs against Pf HGXPRT and human HGPRT 
g. Bisphosphonate aza-ANPs  
By merging the scaffold of N-branched ANPs (AIP and aza-ANPs) and bisphosphonate ANPs (ANbPs) 
described previously, Hockova et al. proposed bisphosphonate aza-acyclic nucleosides (Figure 29: ). 128 
In theory, these compounds should form a tight drug-enzyme complex. Indeed, the presence of the nitrogen 
atom allows triple anchoring of the compound through the nucleobase and the formation of two 
phosphonate chains of different lengths. One phosphonate tail was designed to fill the Pf HGXPRT 
pyrophosphate binding site and the other one the phosphate binding pocket. The main chain included five 
atoms, which was found to be the optimum length for this target. Studies on their affinity towards human, 
Pf and Pv PRTases showed that the addition of a second phosphonate group seemed to create new 
interactions at the active site with the human enzyme, which may have been responsible for the 
improvement in all Ki values compared to their monophosphonate analogues (Figure 29). These 
compounds however remained poorly selective for the parasite enzymes. 
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Figure 29: Generic structure of the aza-ANPs bisphosphonates and first derivatives studied 
 
Modification of the length of the side chain and incorporation of an oxygen atom were then envisaged 
(Figure 30).129 Regardless of the nature of the second phosphonate tail, guanine derivatives showed 
similar or better affinity for human HGPRT, with Ki values in the sub-micromolar range. The increased 
length of the side chain to eight atoms and the presence of oxygen atoms led in all cases to more potent 
inhibitors for all three enzymes. In this case, selectivity was in favor of the parasite enzymes for 
hypoxanthine and 8-bromoguanine derivatives.  
Due to the polyanionic nature of the parent compounds, only the corresponding phosphoramidate 
prodrugs were tested in cell experiments (Pf D6 and W2 strains), and cytotoxicity was assessed on human 
lung carcinoma A549 cells. The prodrugs exhibited similar IC50 values, in the micromolar range, against 
both Pf W2 and D6 strains, with weak cytotoxicity against mammalian cells (SI for prodrugs ≥ 15).  
Extensive structural studies revealed that the main phosphonate chain was located in the 5’-
phosphate binding pocket, whereas the other chain was hosted by the PPi binding site. The importance of 
coordination of the magnesium ion with the second phosphonate moiety through a water molecule for 
tight binding was highlighted. It was also found that 8-bromoguanine induced inversion of the common 
positioning of the two phosphonate chains and led to occupation of the 5’-phosphate binding site by the 
second phosphonate group, not by the main one. The longer chain can enter deeply into the binding site, 
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and forming strong interactions. Finally, the hydrogen bond interactions of amino acid residues in the 
active site with the purine ring have been described and the most important ones were identified (hydrogen 
bond between V187 and the N1 of the purine ring is present in every case). The authors also observed a 
hydrogen bond between the N3 of the purine ring and water.129 
 
Figure 30: Biological activities of asymmetric aza-bisphosphonate-ANPs and their prodrugs 
 
h. Triazolo-ANPs 
Recently, ANPs containing a triazole ring instead of a ribose ring and a phosphonic acid group at 
position 4 were reported (Figure 31).130 Both guanine enantiomers exhibited the same Ki on purified Pf 
and human HG(X)PRT, which surprisingly indicated that stereoisomery had no effect on affinity. Also 
surprisingly, the xanthine compound showed the best selectivity for Pf enzymes among others (SI > 250). 
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Hypoxanthine compounds were found to be modest inhibitors of Pf and human HG(X)PRT ((R)-isomer 
Ki values of 3 and 8 µM were observed, respectively) and poorly active against Pv HGXPRT (Ki >100 
µM). 
 
Figure 31: Triazolo-ANPs as potent inhibitor of Pf HGXPRT and Hs HGPRT  
 
CONCLUSION 
As the resistance of Plasmodium species to all antimalarial medicines is spreading in Asia and 
Africa, the search for new treatments is crucial. The main recommendations of WHO to address the drug-
resistance problem include the use of a single-dose treatment to cure uncomplicated malaria, safety for 
vulnerable persons such as pregnant women and young children, combining drugs with different targets, 
activity against several stages of the parasite life cycle and low cost (~ US$1 per adult and US$0.60 for 
an average child's treatment). Consequently, the scientific community, especially medicinal chemists, 
biochemists and biologists working in the field of parasitology, is still facing a challenge to discover 
original drugs and identify novel targets.  
Here we have discussed nucleos(t)ide analogues as a class of potential antimalarials and the related 
metabolic pathway, i.e. enzymes belonging to the purine salvage pathway which have been investigated 
for chemotherapy. Indeed, Plasmodium parasites behave as purine auxotrophs and inhibition of the 
corresponding enzymes would lead to death of the parasites through purine starvation. Among the possible 
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targets, Pf PNP and Pf HGXPRT inhibition has been intensively investigated, along with Pf ADA and Pf 
IMPDH to a lesser extent. Molecular modelling approaches have been used to improve potential inhibitors. 
However, the weak (or the lack) of specificity of many compounds towards human and Pf species has 
somewhat limited their development as drug candidates. The antimalarial activity of immucillin 
derivatives and analogues has been demonstrated in vitro and in vivo. Within this class, DADMe-
immucillin-G (BCX4945) was identified as one of the most potent Pf PNP inhibitors (with subnanomolar 
affinity) while acting as a transition state analogue. This compound reached the preclinical phase in 2012, 
but no further information has been reported since then. The use of ANPs as inhibitors of the plasmodial 
purine metabolism was proposed in the late 1990s, and investigations are still ongoing. It could represent 
one of the most promising families of derivatives. Various series of ANPs have been reported to inhibit Pf 
HGXPRT and Pv HGPRT, leading to studies on the impact of the nucleobase nature, linker length, the 
presence of side-chains and their functionalities on the activity and selectivity. Docking studies were also 
performed to enhance their affinity and/or selectivity. However, the unknown structure of Pf HGXPRT is 
a major limitation which could hamper rational design of these derivatives based on docking studies. All 
computational studies have been performed with human and/or Pv HGPRT, which is not entirely 
comparable to the Pf HGPRT. In addition, the use of prodrug approaches is mandatory for such compounds 
since phosphonic acids do not readily cross biological membranes—an aspect that could complicate 
matters (i.e. synthesis and cost). 
The overall findings of all of these studies show us that nucleos(t)ide analogues are far from revealing 
their full potential. Two decades have been enough to develop a broad range of compounds effectively 
and selectively targeting different enzymatic steps of the Plasmodium purine salvage pathway, and it is 
hoped that the future of this class of compounds will meet with the success it deserves.  
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ABBREVIATION USED  
6-oxoPRTases or 6-oxopurinePRTs, 6-oxopurinephosphoribosyltransferases; A, adenine; ABC, ATP-
binding cassette; ABS, asexual blood stage; ACTs, artemisinin combination therapies; ADA, adenosine 
deaminase; ADC, aminodeoxychorismate; ADCL, aminodeoxychorismate lyase; ADCS, amino-
deoxychorismate synthase; ADP, adenosine 5’-diphosphate; AdSL, adenylosuccinate lyase; AdSS, 
adenylosuccinate synthase; AIP, acyclic immucillin phosphonate; AMPDA, adenosine-5’-monophosphate 
deaminase; ANbPs, acyclic nucleoside bisphosphonates; ANPs, acyclic nucleoside phosphonate; ATC, 
aspartate transcarbamoylase; ATP, adenosine 5’-triphosphate; ATPPase, adenosine 5’-triphosphate 
pyrophosphatase; BCX-1777, immucillin-H; BT1 family, high affinity folate-biopterin transporters C; 
cytosine CA, carbonic anhydrase; CC50, 50% cytotoxic concentration; CH2.THF, 5,10-methylene-
tetrahydrofolate; CH.THF, 5,10-methenyltetrahydrofolate; CoQ, co-enzyme; QCPEE, (S)-2-
(phosphonoethoxy)propanoic acid; CPME, (S)-2-(phosphonomethoxy)propanoic acid; CPSII, carbamoyl 
phosphate synthetase; IICS, chorismate synthase; CTP, cytidine-5’-triphosphate; CTPS, cytosine 5’-
triphosphate synthetase; CVPS, 5-O-(1-carboxyvinyl)-3-phosphoshikimatecyclic; HPMP, cyclic-3-
hydroxy-2-(phosphonomethoxy)-propyl; DADMe, 4’-deaza-1’-aza-2’-deoxy-1’-(9-methylene); DAP, 
2,6-diaminopurine; DATMe : , 4’-deaza-1’-aza-triol-1’-(9-methylene); dCTP, 2’-deoxycytidine-5’-
triphosphated; GMP, 2’-deoxyguanosine-5’-monophosphate; DHF, 7,8-dihydrofolate; DHFR, 
dihydrofolate reductase; DHNTP, 7,8-dihydroneopterin triphosphate; DHO, dihydroorotase; DHODH, 
dihydroorotate dehydrogenase; DHP, 7,8-dihydropteroate; DHPA, 9-(2,3-dihydroxypropyl)adenine; DNA, 
desoxyribonucleic acid; DON, 6-diazo-5-oxo-norleucine; DOXP, 1’-deoxy-D-xylulose-5’-phosphate 
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pathway / non-mevalonate pathway; dTMP, 2’-deoxythymidine-5’-monophosphate; dTTP, 2’-
deoxythymidine-5’-triphosphate; dUDP, 2’-deoxyuridine-5’-diphosphate; dUMP, 2’-deoxyuridine-5’-
monophosphate; dUTP, 2’-deoxyuridine-5’-triphosphate; dUTPase, deoxyuridine 5’-triphosphate 
nucleotidohydrolase; EC50, 50% effective concentration ; EMP1, erythrocyte membrane protein 1 ; 
ENT1/2/3/4, equilibrative nucleoside transporter 1/2/3/4; EPSPS, 5-enolpyruvylshikimate-3-phosphate 
synthase ; FUdR, 5-fluoro-D-2’-deoxyuridine ; FMet-tRNA, formylmethionyl-tRNA ; FPEP, 3-fluoro-(2-
phosphonoethoxy)propyl ; FPGS, folylpolyglutamate synthase ; FPMP, 3-fluoro-(2-phosphono-
methoxy)propyl; FOCM, folate-mediated one-carbon metabolism; FT1/2, folate/biopterin transporter 1/2; 
G, guanine; GAT, domain of GMPS responsible of glutamine hydrolyzation; GMP, guanosine 
monophosphate; GMPs, guanosine monophosphate synthetase; GTP, guanosine 5’-triphosphate; GTPC, 
GTP cyclohydrolase I; bis(POM)PMEA, bis(pivaloyloxymethyl)-9-[2-(phosphonomethoxy)ethyl]-
adenine, brand name Adefovir; dipivoxil HBV, hepatitis B virus; HGPRT, hypoxanthine-guanine 
phosphoribosyltransferase (human); HGXPRT, hypoxanthine-guanine-xanthine phosphoribosyl-
transferase (malarial); HG(X)PRT, both human HGPRT and malarial HGXPRT; Hs, Homo sapiens; HIV, 
human immunodefiency virus; HMDP, 6-hydroxymethyl-7,8-dihydropterin; HMDP-PP, 6-
hydroxymethyl-7,8-dihydropterin pyrophosphate; HomoCys, homocysteine; HPEP, (S)-3-hydroxy-2-
(phosphonoethoxy)propyl; HPMP, 9-(3-hydroxy-2-phosphonomethoxypropyl); IC37, molar concentration 
of an antagonist that inhibits 37% of the activity of a targeted function in vitro; IC50, 50% inhibitory 
concentration; ID50, 50% infectious dose; Imm, immucillin ; IMP, inosine monophosphate ; IMPDH, 
inosine monophosphate dehydrogenase ; Kd, dissociation constant, measure of the propensity of a complex 
(such as the substrate-enzyme complex) to separate into each of its components; Ki, dissociation constant 
for the enzyme-drug complex, measured from initial rates; Ki*, equilibrium dissociation constant; Me.THF, 
5-methyltetrahydrofolate; Met-tRNA, methionyl-tRNA; MTA, 5’-methylthioadenosine; MTHFD, 
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methylenehydrofolate dehydrogenase; MTHFR, methylenetetrahydrofolate reductase; MTI, 5’-
methylthioinosine; MT-Imm, 5’-methylthioimucillin; NAD+, oxidized nicotinamide adenine dinucleotide 
(coenzyme); NADH, reduced nicotinamide adenine dinucleotide (coenzyme); NBMPR, 
nitrobenzylthioinosine; NDP, nucleoside diphosphate; NMPK, nucleoside monophosphate kinase; NPP, 
new permeability pathway; NTP, nucleoside triphosphate; ODC, orotidine 5’-monophosphate 
decarboxylase; OPRTase, orotate phosphoribosyltransferase; pABA, para-aminobenzoic acid; Pb, 
Plasmodium berguei; PDB, protein data bank; PEE, 2-(phosphonoethoxy)ethyl; Pf, Plasmodium 
falciparum; Pf3D7, Plasmodium falciparum strain used in lab assays; Pfcrt, Pf chloroquine-resistant 
transporter gene; PfCRT, Plasmodium falciparum digestive vacuole chloroquine-resistant transmembrane 
transporter; PfMDR, Plasmodium falciparum multidrug resistance protein; Pfmdr1, gene of Plasmodium 
falciparum multidrug resistance protein; Pk, Plasmodium knowlesi; pKa, logarithm of acid dissociation 
constant Ka; PlasmoDB, the online plasmodic genomic resources http://PlasmoDB.orgPm: Plasmodium 
malariae; PME, 2-(phosphonomethoxy)ethyl; PMP, 2-(phosphonomethoxy)propyl; PNP, purine 
nucleoside phosphorylase; Po, Plasmodium ovale; PPi : inorganic pyrophosphate; PRib-PP, 
phosphoribosyl pyrophosphate; PSAC, plasmodial surface anion channel; PTPS, 6-pyruvoyl-
tetrahydropterin synthase III; Pv, Plasmodium vivax; PVM, parasitophorous vacuole membrane; RBC, 
red blood cell; RNA, ribonucleic acid; RNR, ribonucleotide reductase; ROS, reactive oxygen species; 
SHMT, serine hydroxymethyltransferase; SK, shikimate kinase; T, thymine; THF, 5,6,7,8-tetrahydrofolate; 
TK, thymidine kinase; TMP, thymidine-5’-monophosphate; TMPK, thymidylate monophosphate kinase; 
tRNA, transfer ARN; TS, thymidylate synthase; UDP, uridine-5’-diphosphate; UK, uridine kinase; UPRT, 
uracile phosphoribosyltransferase; UTP, uridine-5’-triphosphate; WHO, world health organization; XMP, 
xanthosine monophosphate. 
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